Want to see JP:4583 full AI Analyst Report?
Top Page
Chiome Bioscience Inc.
(4583)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥100.00
▼(-5.66% Downside)
Action:Reiterated
Date:09/08/26
The score is primarily weighed down by persistent large losses and sustained cash burn despite low leverage on the balance sheet. Technicals are a key offset, with price trading above major moving averages and positive momentum indicators. Valuation remains challenged due to negative earnings (negative P/E) and no stated dividend yield.
Positive Factors
Low financial leverage
Modest leverage gives Chiome greater financial flexibility than a highly indebted biotechnology company. Lower debt obligations can reduce interest and refinancing pressure, preserve funding choices, and provide a stronger buffer while the company develops therapeutic candidates.
Negative Factors
Declining and volatile revenue
Revenue volatility and the sharp 2025 decline weaken visibility into the company’s ability to scale its biotechnology activities. Without a sustained top-line recovery, fixed research and development spending is harder to absorb and progress toward profitability remains uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Modest leverage gives Chiome greater financial flexibility than a highly indebted biotechnology company. Lower debt obligations can reduce interest and refinancing pressure, preserve funding choices, and provide a stronger buffer while the company develops therapeutic candidates.
Read all positive factors
Chiome Bioscience Inc. (4583) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.17B
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth-19.99%
EPS Growth16.36%
CountryJP
Employees49
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-13.11
Shares Outstanding81,863,700
10 Day Avg. Volume2,121,140
30 Day Avg. Volume1,054,373
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)6.47
Price to Sales (P/S)12.25
P/FCF Ratio-7.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chiome Bioscience Inc. Business Overview & Revenue Model
Company Description
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technolog...
How the Company Makes Money
Publicly available, company-specific details on Chiome Bioscience Inc.’s current revenue model and the breakdown of its revenue streams (e.g., product sales vs. licensing, collaboration milestones, research funding, or royalties), as well as signi...
Chiome Bioscience Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 615.15M | 593.29M | 780.81M | 682.46M | 630.82M | 712.93M |
| Gross Profit | 375.24M | 355.58M | 432.02M | 397.72M | 347.78M | 420.59M |
| EBITDA | -910.50M | -972.64M | -1.01B | -1.21B | -1.24B | -1.46B |
| Net Income | -925.73M | -982.78M | -1.02B | -1.22B | -1.24B | -1.48B |
Balance Sheet | ||||||
| Total Assets | 1.91B | 1.73B | 2.47B | 1.75B | 2.22B | 2.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 1.21B | 2.06B | 1.33B | 1.73B | 1.79B |
| Total Debt | 67.50M | 261.70M | 281.50M | 291.00M | 184.00M | 183.00M |
| Total Liabilities | 341.26M | 605.44M | 548.55M | 593.73M | 424.72M | 446.39M |
| Stockholders Equity | 1.57B | 1.12B | 1.92B | 1.16B | 1.79B | 1.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -976.07M | -1.00B | 0.00 | -1.19B | 0.00 |
| Operating Cash Flow | 0.00 | -935.99M | -1.00B | -1.07B | -1.19B | -1.13B |
| Investing Cash Flow | 0.00 | -55.46M | 0.00 | 173.00K | 0.00 | -35.38M |
| Financing Cash Flow | 0.00 | 133.20M | 1.74B | 667.30M | 1.13B | 271.35M |
Chiome Bioscience Inc. Technical Analysis
Positive
106.00
Price Trends
77.06
Positive
81.66
Positive
96.75
Positive
Market Momentum
5.36
Negative
65.61
Neutral
59.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Positive. The current price of 106 is above the 20-day moving average (MA) of 84.15, above the 50-day MA of 77.06, and above the 200-day MA of 96.75, indicating a bullish trend. The MACD of 5.36 indicates Negative momentum. The RSI at 65.61 is Neutral, neither overbought nor oversold. The STOCH value of 59.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4583.
Chiome Bioscience Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥9.89B | 26.86 | ― | 0.65% | 13.46% | 42.41% | |
58 Neutral | ¥14.29B | 61.34 | ― | ― | 20.64% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥9.17B | -8.54 | ― | ― | -19.99% | 16.36% | |
50 Neutral | ¥105.58B | -13.20 | -12.23% | 0.33% | 7.12% | -137.21% | |
50 Neutral | ¥135.23B | -83.61 | ― | ― | 1662.38% | 42.86% | |
48 Neutral | ¥138.78B | -38.03 | -7.17% | ― | 0.62% | 27.66% |
* General Sector Average
JP:4583
Chiome Bioscience Inc.
99.00
-41.00
-29.29%
JP:4587
Peptidream
1,088.50
-626.50
-36.53%
JP:4565
Sosei Group
1,168.00
133.00
12.85%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
1,151.00
680.02
144.38%
JP:4579
RaQualia Pharma Inc.
552.00
-34.00
-5.80%
JP:4588
Oncolys BioPharma, Inc.
4,950.00
4,294.00
654.57%
Chiome Bioscience Inc. Corporate Events
Chiome Bioscience Outlines Q2 FY2026 Results and R&D Focus
Aug 13, 2026
Chiome Bioscience has released supplementary information for its second-quarter fiscal 2026 results, outlining financial performance and operational highlights for the period. The materials also reference updates to the company’s therapeutic...
Chiome Bioscience Narrows Losses as Sales Rise and Balance Sheet Strengthens
Aug 13, 2026
Chiome Bioscience reported non-consolidated net sales of ¥273 million for the six months ended June 30, 2026, an 8.7% increase year on year, while narrowing its net loss to ¥483 million as operating and ordinary losses also improved. Tot...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.